Retrophin Reports First Quarter 2019 Financial Results
07 mai 2019 16h01 HE
|
Retrophin, Inc.
Top-line results from pivotal Phase 3 FORT Study in PKAN on-track for 3Q 2019 Enrollment ongoing in Phase 3 clinical trials of sparsentan for patients with rare nephropathies FSGS and IgAN Continued...
Retrophin to Report First Quarter 2019 Financial Results
23 avr. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, April 23, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced it will report first quarter 2019 financial results on Tuesday, May 7, 2019 after the close of the U.S....
Retrophin to Present at Upcoming Investor Conferences
05 mars 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, March 05, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Eric Dube, Ph.D., chief executive officer, will present at the following upcoming investor...
Retrophin Provides Corporate Update and 2019 Outlook
07 janv. 2019 07h00 HE
|
Retrophin, Inc.
SAN DIEGO, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that, based on preliminary and unaudited financial data, the Company expects net product sales for the...
Retrophin to Present at the 37th Annual J.P. Morgan Healthcare Conference
02 janv. 2019 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Jan. 02, 2019 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the 37th Annual J.P. Morgan Healthcare...
Retrophin to Present at the BMO Prescriptions for Success Healthcare Conference
28 nov. 2018 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Nov. 28, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the BMO 2018 Prescriptions for Success...
Retrophin Announces U.S. FDA Acceptance of NDA Filing for the New Formulation of Thiola® (tiopronin) in the Treatment of Cystinuria
12 nov. 2018 07h00 HE
|
Retrophin, Inc.
PDUFA date set for June 30, 2019 SAN DIEGO, Nov. 12, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review...
Retrophin to Present at the Jefferies 2018 London Healthcare Conference
07 nov. 2018 16h30 HE
|
Retrophin, Inc.
SAN DIEGO, Nov. 07, 2018 (GLOBE NEWSWIRE) -- Retrophin, Inc. (NASDAQ: RTRX) today announced that Stephen Aselage, chief executive officer, will present at the Jefferies 2018 London Healthcare...
Robbins Arroyo LLP: Retrophin, Inc. (RTRX) Misled Shareholders According to a Recently Filed Class Action
22 oct. 2014 19h16 HE
|
Robbins LLP
SAN DIEGO and NEW YORK, Oct. 22, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Retrophin, Inc. (Nasdaq:RTRX) has filed a federal securities...